Home Other Navigation Pharmacy + Providers Pharmacy Credentialing Important information Updated Insurance Coverage Information To submit a renewal, submit your updated certificate of insurance to...

A gene therapy product approved for adults with hemophilia B may increase initial costs for health plans but can reduce expenditures by nearly $1 million over time, according to a recent study

In this special episode of the Pharmacy Friends podcast, “Live at Specialty Summit ’24 – Connect. Elevate. Transform.,” we are on the road in New York City at our 21st annual Specialty Summit. More...

This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process.

Effective Date: July 1, 2026 Introduction, scope, and purpose: Prime Therapeutics LLC and all of its operating units and subsidiaries (“Prime,” “we,” “our”) understands that the privacy of your...

Experts outline clinically grounded strategies to manage cost, improve outcomes and coordinate care across benefits

Home News & Insights Research & publications Archived Content High Cost Therapy Profile 2024-2025 High-Cost Therapy Profile: September 2024 Oncology/ cellular therapy Obecabtagene autoleucel...

In the U.S. Food and Drug Administration (FDA)’s latest annual report of drug approvals, the agency shared it approved a total of 46 novel drugs in 2025. Here’s how that stacks up against years...